VMVeronika Matušková

Veronika Matušková

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Veronika Matušková has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • GNAQ Mutation in Uveal Melanomas is Associated with Histological Type: A Cytogenetic Study Comparing Clinicopathological Characteristics, Chromosomal Abnormalities, and GNA11 Mutations

    by Veronika Matuskova, Pavla Hornackova, Kvetoslava Matulova, Lenka Zlamalikova, Michal Uher, Nora Majtanova, Iveta Valaskova, Oldrich Chrapek

  • Open Access

    Retinal Vessel Oxygen Saturation in Patients with Unilateral Edema of the Optic Nerve Head: A Pilot Study

    by Michal Březík, Veronika Matušková, Daniela Vysloužilová, Martin Šín, Veronika Chovancová, Kristína Sičová, Natália Jankaničová, Oldřich Chrapek

    Purpose: Evaluate whether optic disc edema results in changes in retinal microcirculation. Patients and Methods: The study group consisted of 11 patients with unilateral optic disc edema (papilledema). The control group consisted of the healthy eyes of the same 11 patients. Patients underwent non-invasive photo-spectrometric retinal oximetry using Oxymap T1 retinal oximeter (Oxymap, Reykjavik, Iceland). In the eyes of these 11 patients, we examined the diameter of the retinal arteries and veins, arterial and venous blood oxygen saturation, and the difference in oxygen saturation between arterioles and venules (A-V difference). Results: In the papilledema group, the decrease in the retinal arterial diameter was statistically significant (p=0.001). The median diameter of the retinal artery was 11.70 px (IQR 1.47) or after conversion 109.00 μm (IQR 14.00) in the papilledema group and 13.75 px (IQR 1.61) or 128.00 μm (IQR 15.00) in the control group. The increase in the diameter of the retinal veins in the papilledema group was statistically significant (p=0.012), where the median diameter in the papilledema group was 20.88 px (IQR 3.72) or 194.00 μm (IQR 35.00), and in the control group was 18.18 px (IQR 3.60) or 169 μm (IQR 33.00). There was a statistically significant decrease (p< 0.001) in the venous saturation in the papilledema group with a median value of 53.16% (IQR 17.38) and 60.02% (IQR 11.98) in the control group. The median of the A-V difference was 51.92 (IQR 15.96) in the papilledema group, resp. 38.49 (IQR 9.75) in the control group and a significant increase in the papilledema group (p< 0.001) was reported. Conclusion: Automatic retinal oximetry demonstrated changes in the retinal microcirculation in patients with optic disc edema.


  • Open Access

    Unveiling the Cellular and Molecular Mechanisms of Diabetic Retinopathy with Human Retinal Organoids

    by Lada Polešovská, Simona Trmačová, Canan Celiker, Eva Hrubá, Francisco Molina Gambin, Veronika Matušková, Eleni Beli, Tomáš Bárta

    Diabetic retinopathy (DR) is a leading cause of vision impairment worldwide, driven by chronic hyperglycaemia and its complex metabolic consequences. While animal models have been widely used to study DR, they often fail to replicate the physiology of human retina. To address this limitation, we employed human retinal organoids as a model to study the effects of hyperglycaemia across various stages of retinal differentiation. Early-stage organoids demonstrated resilience to high glucose levels, maintaining normal morphology, viability, and gene expression. However, advanced-stage organoids displayed significant disruptions, including the downregulation of outer segment-specific genes, which impaired photoreceptor maturation, and a noticeable shortening of photoreceptor outer segments. Transcriptomic analysis revealed substantial changes in pathways related vision including G protein-coupled receptor signalling pathway, response to light stimulus, and visual perception. While photoreceptors were particularly vulnerable, other retinal cell types, including bipolar cells, ganglion cells, and Müller glia, showed greater resilience. Additionally, glial activation, evidenced by increased expression of astrocyte markers, suggested an adaptive response to hyperglycaemia. To validate our findings, we compared our dataset with publicly available transcriptomic datasets from human retinas with DR, confirming key overlaps in pathways related to photoreceptor dysfunction, gliogenesis, and oxidative stress responses. These results establish human retinal organoids as an effective and relevant model for studying the molecular mechanisms of neurodegeneration associated with DR progression.


  • Cancer Diseases

    by Veronika Matuskova, Jiri Petera, Ondrej Kubecek, Ahmed Youbi Zakaria

  • Blood Diseases

    by Alexandr Stepanov, Jakub Radocha, Veronika Matuskova


  • Open Access

    Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

    by Neil M Bressler, Miroslav Veith, Jan Hamouz, Jan Ernest, Dominik Zalewski, Jan Studnička, Attila Vajas, András Papp, Gabor Vogt, James Luu, et al.

    Background/Aims: To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).Methods: Setting: Multicentre.Design: Randomised, double-masked, parallel-group, phase III equivalence study.Patient population: ≥50 years old participants with nAMD (n=705), one ‘study eye’. Intervention: 1:1 randomisation to monthly intravitreal injection of 0.5 mg SB11 or RBZ.Main outcome measures: Visual efficacy endpoints, safety, immunogenicity and PK up to 52 weeks.Results: Baseline and disease characteristics were comparable between treatment groups. Of 705 randomised participants (SB11: n=351; RBZ: n=354), 634 participants (89.9%; SB11: n=307; RBZ: n=327) completed the study until week 52. Previously reported equivalence in primary efficacy remained stable up to week 52 and were comparable between SB11 and RBZ. The adjusted treatment difference between SB11 and RBZ in full analysis set at week 52 of change from baseline in best-corrected visual acuity was −0.6 letters (90% CI −2.1 to 0.9) and of change from baseline in central subfield thickness was −14.9 µm (95% CI –25.3 to –4.5). The incidence of ocular treatment-emergent adverse events (TEAEs) (SB11: 32.0% vs RBZ: 29.7%) and serious ocular TEAE (SB11: 2.9% vs RBZ: 2.3%) appeared comparable between treatment groups, and no new safety concerns were observed. The PK and immunogenicity profiles were comparable, with a 4.2% and 5.5% cumulative incidence of antidrug antibodies up to week 52 for SB11 and RBZ, respectively.Conclusions: Longer-term results of this study further support the biosimilarity established between SB11 and RBZ.


  • Open Access

    Uveal melanoma - testing of abnormalities of chromosome 3 and 8 in the Czech Republic

    by Veronika Matuskova, Pavla Hornackova, Radoslava Uhmannova, Lenka Zlamalikova, Kvetoslava Liskova, Michal Uher, Eva Vlkova

    Aim: The aim of this cytogenetic study is to confirm the significance of chromosome 3 loss (monosomy 3) and of the gain of chromosome 8 as prognostic markers in histopathological samples of enucleated eyes with uveal melanoma in the Czech popu...


  • An association of neovascular age‐related macular degeneration with polymorphisms of CFH, ARMS2, HTRA1 and C3 genes in Czech population

    by Veronika Matušková, Tomáš Zeman, Laura Ewerlingová, Zuzana Hlinomazová, Jan Souček, Eva Vlková, Nandu Goswami, Vladimir J. Balcar, Omar Šerý

    Purpose: We investigated associations between neovascular age‐related macular degeneration (AMD) and rs10490924 polymorphism of ARMS2 gene (age‐related maculopathy susceptibility 2), rs1061170 polymorphism of gene for complement factor H (CFH), rs2230199 polymorphism of gene for complement component C3 and rs11200638 polymorphism of gene for serine protease high‐temperature requirement A1 (HTRA1) in the Czech population.Methods: We analysed samples of DNA from 307 patients diagnosed with neovascular form of late AMD (average age: 73.7 ± 7.7 years) and 191 control subjects, recruited from patients awaiting cataract surgery (average age, 73.6 ± 8.7 years).Results: HTRA1, CFH and ARMS2 genes polymorphisms were found to be related to neovascular AMD in the Czech population. All analysed polymorphisms were statistically significantly associated with neovascular AMD, with stronger associations in females than in males. In whole group, CC genotype of CFH gene polymorphism, TT genotype of ARMS2 gene polymorphism and AA genotype of HTRA1 gene polymorphism showed the greatest risk for neovascular AMD with odds ratios equal to 8.43, 10.07, 9.83, respectively (p < 0.0001). Only CG polymorphism of C3 gene showed statistically significant risk for neovascular AMD. In addition, we observed an association between waist circumference and neovascular AMD in both sexes, which further suggests the significance of excessive abdominal fat as a risk factor of AMD. We found a statistically significant association between polymorphisms in HTRA1, CFH and ARMS2 genes and neovascular AMS in the Czech population. The association was stronger in females than in males.Conclusion: We demonstrated a relationship between neovascular AMD and genes for HTRA1, CFH, ARMS2 and C3 in Czech population. To our knowledge, the relationship between these polymorphisms and neovascular AMD in Czech population has never been investigated before.


  • Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes

    by Veronika Matušková, Daniela Vysloužilová, Michal Uher

    Background: Central serous chorioretinopathy (CSC) is characterised by a serous detachment of the neurosensory retina in the macula. Chronic CSC tends to affect older individuals with a less favourable visual outcome. Photodynamic therapy (PDT) with verteporfin is a possible therapeutic approach in cases of CSC with no tendency for spontaneous resorption. PDT has shown good anatomic and functional results in treating chronic CSC. For the purpose of diminishing side effects, modifications of the standard protocol were used. Materials and Methods: This is a retrospective study of 32 eyes with CSC of 32 patients treated by half-fluence PDT. The patients underwent complete ophthalmology examination. On optical coherence tomography (OCT) we measured central retinal thickness (CRT), the outer nuclear layer (ONL), presence of subfoveolar detachment of retinal pigment epithelium (PED), disturbance of external limiting membrane (ELM), morphological changes in the inner segment/outer segment (IS/OS) line and retinal pigment epithelium (RPE) atrophy. We evaluated at baseline, 3 and 12 months after PDT. Results: The mean BCVA at baseline was 0.41 ± 0.23 log MAR, the mean BCVA at 3 months was 0.24 ± 0.20 and at the end of the follow-up it was 0.23 ± 0.200. We observed statistically significant improvements of visual acuity after 3 and 12 months (p < 0.001, Wilcoxon test). The mean central retinal thickness at baseline was 373 ± 87 µm, the mean CRT after 3 months was 234 ± 42 µm and after 12 months 223 ± 39 µm. A significant reduction from baseline was seen after 3 months and 12 months (p < 0.001, Wilcoxon test). Baseline ONL reached 80 ± 27 µm, after 3 months it was 78 ± 20 and after 12 months it was 74 ± 20 µm. We observed a statistically significant change in diminishing the amount of PED after PDT after 3 months and after 12 months (p = 0.021, McNemar’s test). We observed that in patients with RPE ablation, there is lower chance for the restitution of the IS/OS layer (p = 0.045, Mann–Whitney test). We observed a negative association between the improvement of visual acuity after 12 months and the presence of RPE ablation (p = 0.031, Mann–Whitney test). Restitution of ELM was significantly more often in patients with shorter duration of symptoms, (p = 0.027 after 3 months, p = 0.033 after 12 months after PDT, Spearman correlation). Neither ocular nor systemic adverse effects were observed during the follow-up period. Conclusions: Half-fluence PDT treatment has shown to be a usually safe and often effective therapy in patients with chronic CSC. This study suggests that the most important predictive factor is baseline visual acuity. The important anatomical change detected using OCT is a thinning of the outer nuclear layer. Nonetheless, other studies with a larger number of patients and a longer follow-up are required.


  • CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy

    by Veronika Matušková, Vladimir J. Balcar, Naim A. Khan, Ondřej Bonczek, Laura Ewerlingová, Tomáš Zeman, Petr Kolář, Daniela Vysloužilová, Eva Vlková, Omar Šerý

    Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms. Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients’ DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene. Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG). Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.